Core Viewpoint - A shareholder has filed a securities class action lawsuit against C3.ai, Inc. for alleged misrepresentations regarding the company's business and the impact of the CEO's health on its operations [1][2]. Group 1: Lawsuit Details - The lawsuit claims that C3.ai's management failed to address the significant impact of the CEO's health on the company's ability to close deals and execute its profit and growth potential [2]. - Investors who purchased C3.ai securities between February 26, 2025, and August 8, 2025, are included in the class [1]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file papers by October 21, 2025, and representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4].

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”, of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Snap Inc. (“Snap” or the “Company”) (NYSE: SNAP) between April 29, 2025, and August 5, 2025, inclusive. For more information, submit a form at Snap Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030. A ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Flywire Corporation securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Flywire securities between February 28, 2024, and February 25, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 23, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that throughout the Class Period, Flywire's defendants made false and misleading statements regarding the sustainability of the company's revenue growth and the impact of permit and visa-related restrictions on its business [5]. - The lawsuit claims that these misleading statements resulted in investor damages when the true details about Flywire's business performance became public [5].

Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint analysis [1][2]. Group 1: Company Performance - The IMPACT Phase 2b MASH trial results were released on June 26, 2025, revealing that while there was a positive trend in fibrosis improvement, the results did not meet statistical significance due to a higher-than-expected placebo response [1]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [1]. Group 2: Legal Actions - Shareholders who purchased shares of Altimmune during the class period from August 10, 2023, to June 25, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointments in a class action lawsuit [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 6, 2025 [2]. Group 3: Firm's Commitment - The Gross Law Firm is dedicated to protecting the rights of investors affected by deceitful practices and aims to ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit, styled Jboor v. Replimune Group, Inc., et al., No. 1:25-cv-12085 (D. Mass.), has been filed and seeks to represent investors who purchased or otherwise acquired Replimune (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025. The lawsuit comes after Replimune investors witnessed a 77% collapse in the price of their shares on July 22 when the company announced that the Food and Drug Administration (FDA) had re ...

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) securities between March 29, 2024 and June 27, 2025, inclusive (the "Class Period"). The Complaint alleges that Defendants made false and/or misleading st ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and illegal kickbacks related to Medicare beneficiaries [4][6][7]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of the quality of the plans [6]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans and received illegal kickbacks from insurers [6]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021, leading to a significant drop in stock price [7]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $75,000 between September 9, 2020, and May 1, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1][4]. - There is a deadline of October 10, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against SelectQuote [4]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed challenges affecting the company's performance [4][6]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $75,000 in RxSight between November 7, 2024, and July 8, 2025, to discuss their legal options [1]. - There is a deadline of September 22, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against RxSight [4]. - The complaint alleges that RxSight and its executives made false statements regarding the company's sales and utilization, overstated product demand, and failed to meet previously issued financial guidance for fiscal year 2025 [6]. Group 2: Financial Performance and Stock Impact - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full-year guidance by approximately $42.5 million at the midpoint [7]. - Following the announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [7].

Core Viewpoint - A class action lawsuit has been filed against XPLR Infrastructure, LP (formerly Nextera Energy Partners, LP) for misleading statements made during the Class Period from September 27, 2023, to January 27, 2025, potentially affecting investors' rights and financial interests [1][5]. Group 1: Lawsuit Details - The lawsuit alleges that XPLR was struggling to maintain its operations as a yieldco, which is a business model focused on delivering cash distributions to investors [5]. - Defendants reportedly made false and misleading statements regarding the company's financial health and operational sustainability, which led to investor damages when the truth was revealed [5]. - The lawsuit claims that XPLR entered into financing arrangements to temporarily alleviate operational issues but downplayed the associated risks, ultimately leading to a halt in cash distributions to investors [5]. Group 2: Investor Information - Investors who purchased XPLR common units during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must be appointed by September 8, 2025, to represent the interests of other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its success in securities class action settlements and has consistently ranked among the top firms in this area since 2013 [4].